Characterising treatment outcomes of patients achieving quarterly aflibercept dosing for neovascular age-related macular degeneration: real-world clinical outcomes from a large tertiary care centre.
Dun Jack FuDaren HanumunthaduTiarnan D L KeenanSiegfried WagnerKonstantinos BalsakasPearse Andrew KeanePraveen J PatelPublished in: Eye (London, England) (2022)
68% of eyes were able to achieve a q12 injection dose within the first 2 years of treatment. Eyes achieving a q12 injection in the first 2 years achieved a similar visual acuity outcome at both 1 and 2-year follow-up to those unable to do so, with a fewer number of total injections.